Idiopathic Pulmonary Fibrosis

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975

Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement

Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2013) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,642

Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017.

MacMahon, H., Naidich, D. P., Goo, J. M., Lee, K. S., Leung, A. N. C., Mayo, J. R., Mehta, A. C., Ohno, Y., Powell, C. A., Prokop, M., et al. (2017) · Radiology · doi:10.1148/radiol.2017161659 · Cited by 2,491

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline

Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916

Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis

The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,654

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444

Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis

Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357

A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation

Weill, D., Benden, C., Corris, P. A., Dark, J. H., Davis, R. D., Keshavjee, S., Lederer, D. J., Mulligan, M. J., Patterson, G. A., Singer, L. G., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.014 · Cited by 1,329

Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients

Nili, M., Epstein, A. J., Nunag, D., Olson, A. L., & Borah, B. J. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02496-3 · Cited by 12

Inhibition of LPA-LPAR1 and VEGF-VEGFR2 Signaling in IPF Treatment

Luo, Y.-L., Li, Y., Zhou, W., Wang, S., & Liu, Y. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s415453 · Cited by 12

Divergent roles of the Hippo pathway in the pathogenesis of idiopathic pulmonary fibrosis: tissue homeostasis and fibrosis

Kizawa, R., Araya, J., & Fujita, Y. (2023) · Inflammation and Regeneration · doi:10.1186/s41232-023-00295-1 · Cited by 15

No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis

Hoffman, T. W., van Moorsel, C. H. M., van der Vis, J. J., Biesma, D. H., & Grutters, J. C. (2023) · ERJ Open Research · doi:10.1183/23120541.00131-2023 · Cited by 14

Assessment and Management of Cough in Idiopathic Pulmonary Fibrosis: A Narrative Review

Liu, S., & Ye, X. (2023) · Lung · doi:10.1007/s00408-023-00653-3 · Cited by 12

A comprehensive cuproptosis score and associated gene signatures reveal prognostic and immunological features of idiopathic pulmonary fibrosis

Jing, C., Fu, R., Liu, X., Zang, G., Zhu, X. L., Wang, C., & Zhang, W. Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1268141 · Cited by 12

Metabolism and bioenergetics in the pathophysiology of organ fibrosis

Miguel, V., Alcalde‐Estévez, E., Sirera, B., Rodríguez‐Pascual, F., & Lamas, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.06.001 · Cited by 13

Wogonin protects against bleomycin-induced mouse pulmonary fibrosis via the inhibition of CDK9/p53-mediated cell senescence

Wang, L., Lin, F., Liu, Y., Li, W., Ding, Q., Duan, X., Yang, L., Bai, Z., Zhang, M., & Guo, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1407891 · Cited by 13

Emerging roles of noncoding RNAs in idiopathic pulmonary fibrosis

Wang, H., Sun, K., Peng, H. F., Wang, Y., & Zhang, L. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02170-5 · Cited by 14

Rosa roxburghii Fermentation Broths Attenuate Bleomycin‐Induced Pulmonary Fibrosis by Activating the Nrf2/ HO ‐1/ NQO1 Signaling Pathway and Modulating Gut Microbiota

Zhou, H., Zheng, X., Huang, S., Wang, X., Zhou, T. J., Zhang, S., Ling, Y., Wang, W., Li, X., Li, S., et al. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70105 · Cited by 12

A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis

Wang, J. M., Adegunsoye, A., Pugashetti, J. V., Lee, C. T., Murray, S., Mohan, N., Nazemi, N., Kang, E., Chelala, L., Kazerooni, E. A., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202501-0208oc · Cited by 12

Comprehensive Bioinformatics Identifies Key microRNA Players in ATG7-Deficient Lung Fibroblasts

Stojanović, S. D., Fuchs, M., Fiedler, J., Xiao, K., Meinecke, A., Just, A., Pich, A., Thum, T., & Kunz, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114126 · Cited by 13

Study of the common activating mechanism of apoptosis and epithelial-to-mesenchymal transition in alveolar type II epithelial cells

Wang, J., Xue, T., Ye, H., Sang, C., Wu, S., & Li, S. (2020) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2020.103584 · Cited by 12

Protective Effects of Extracellular Matrix-Derived Hydrogels in Idiopathic Pulmonary Fibrosis

Evangelista-Leite, D., Carreira, A. C. O., Gilpin, S. E., & Miglino, M. A. (2021) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2020.0357 · Cited by 12

Network Pharmacology Prediction and Molecular Docking-Based Strategy to Discover the Potential Pharmacological Mechanism of Wen-Yu-Jin against Pulmonary Fibrosis in a Mouse Model

Wang, L., Zhu, W., Sun, R., Liu, J., Ma, Q., Zhang, B., & Shi, Y. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/7753508 · Cited by 10

Integrated bioinformatics analysis identifies established and novel TGFβ1-regulated genes modulated by anti-fibrotic drugs

Wilson, A. C., Chiles, J. W., Ashish, S. Y., Chanda, D., Kumar, P. L., Mobley, J. A., Neptune, E., Thannickal, V. J., & McDonald, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-07151-1 · Cited by 12

Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis

Pitre, T., Khalid, M. F., Cui, S., Zhang, M. C., Husnudinov, R., Mah, J. C., Helmeczi, W., Su, J. S., Banfield, L., Guy, B., et al. (2022) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2022.102128 · Cited by 12

Role of transient receptor potential vanilloid 4 in therapeutic antifibrotic effects of pirfenidone

Kuronuma, K., Otsuka, M., Wakabayashi, M., Yoshioka, T., Kobayashi, T., Kameda, M., Morioka, Y., Chiba, H., & Takahashi, H. (2022) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00565.2020 · Cited by 12

Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease related interstitial lung disease

Lee, J. M., Kim, K., & Jo, Y. S. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107242 · Cited by 12

Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies

Kaner, R. J., Bajwa, E. K., El-Amine, M., Gorina, E., Gupta, R., Lazarus, H. M., Luckhardt, T., Mouded, M., Posada, K., Richeldi, L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0592pp · Cited by 12

Pathogenesis of fibrosis in interstitial lung disease

Burgy, O., Bellaye, P., Beltramo, G., Goirand, F., & Bonniaud, P. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000706 · Cited by 12

Prematurity negatively affects regenerative properties of human amniotic epithelial cells in the context of lung repair

Zhu, D., Kusuma, G. D., Schwab, R., Chan, S. T., Tan, J. L., Saad, M. I., Leeman, K. T., Kim, C. F., Wallace, E. M., & Lim, R. (2020) · Clinical Science · doi:10.1042/cs20200859 · Cited by 12

Pterostilbene alleviates pulmonary fibrosis by regulating ASIC2

Peng, Y., Zhang, Y., Zhang, Y., Wang, X., Xia, Y., Ye, T., Wu, Z., & Ke, H. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00474-7 · Cited by 12

Lung Fibroblasts from Idiopathic Pulmonary Fibrosis Patients Harbor Short and Unstable Telomeres Leading to Chromosomal Instability

M’kacher, R., Jaillet, M., Colicchio, B., Vasarmidi, E., Mailleux, A., Dieterlen, A., Kannengiesser, C., Borie, C., Oudrhiri, N., Junker, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020310 · Cited by 15

Perlin Noise Generation of Physiologically Realistic Patterns of FibrosisPreprint

Jakes, D., Burrage, K., Drovandi, C., Burrage, P., Bueno‐Orovio, A., dos Santos, R. W., Rodríguez, B., & Lawson, B. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/668848 · Cited by 12

B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents

Roman, J., & Chiba, H. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0101ed · Cited by 12

Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review

Montero, I. E., Hernández‐González, F., & Sellarés, J. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00302-5 · Cited by 11

Identification of the Molecular Subgroups in Idiopathic Pulmonary Fibrosis by Gene Expression Profiles

Zhang, N., Guo, Y., Wu, C., Jiang, B., & Wang, Y. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/7922594 · Cited by 11

Screening of Biomarkers Involved in Idiopathic Pulmonary Fibrosis and Regulation of Upstream miRNAs

Gao, L., Li, P., Tian, H., Wu, M. Y., Yang, J. O., & Xu, X. (2021) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.06.027 · Cited by 11

Autoantibodies are present in the bronchoalveolar lavage but not circulation in patients with fibrotic interstitial lung disease

Boustani, K., Ghai, P., Invernizzi, R., Hewitt, R. J., Maher, T. M., Li, Q., Molyneaux, P. L., & Harker, J. A. (2021) · ERJ Open Research · doi:10.1183/23120541.00481-2021 · Cited by 14

Current and prospective applications of exosomal microRNAs in pulmonary fibrosis (Review)

Yang, T., Wang, J., Zhao, J., & Liu, Y. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5092 · Cited by 12

Synthesis and structure–activity relationships of pirfenidone derivatives as anti-fibrosis agents in vitro

Shi, X., Yu, Z., Zhu, C., Jiang, L., Geng, N., Fan, X., Guan, Z., & Lu, X. Y. (2022) · RSC Medicinal Chemistry · doi:10.1039/d1md00403d · Cited by 11

Caveolin-1 scaffolding domain peptide abrogates autophagy dysregulation in pulmonary fibrosis

Venkatesan, S., Fan, L., Tang, H., Konduru, N. V., & Shetty, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-14832-4 · Cited by 11

Number 2 Feibi Recipe Ameliorates Pulmonary Fibrosis by Inducing Autophagy Through the GSK-3β/mTOR Pathway

Liu, H., Pang, Q., Cao, F., Liu, Z., Wei, W., Li, Z., Long, Q., & Jiao, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.921209 · Cited by 11

Comorbidity and life expectancy in shared decision making for lung cancer screening

Bade, B. C., Gwin, M. E., Triplette, M., Wiener, R. S., & Crothers, K. A. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.07.003 · Cited by 11

A Protective Effect of Pirfenidone in Lung Fibroblast–Endothelial Cell Network via Inhibition of Rho-Kinase Activity

Nakamura, Y., Shimizu, Y., Fujimaki, M., Uchida, N., Takemasa, A., & Niho, S. (2023) · Biomedicines · doi:10.3390/biomedicines11082259 · Cited by 11

Optimization of an Allysine-Targeted PET Probe for Quantifying Fibrogenesis in a Mouse Model of Pulmonary Fibrosis

Shuvaev, S., Knipe, R. S., Drummond, M., Rotile, N. J., Ay, İ., Weigand‐Whittier, J., Ma, H., Zhou, I. Y., Roberts, J. D., Black, K., et al. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01845-2 · Cited by 11

CenTime: Event-conditional modelling of censoring in survival analysis

Shahin, A. H., Zhao, A., Whitehead, A. C., Alexander, D. C., Jacob, J., & Barber, D. (2023) · Medical Image Analysis · doi:10.1016/j.media.2023.103016 · Cited by 11

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond

Sofia, C., Comes, A., Sgalla, G., & Richeldi, L. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2281416 · Cited by 11

Combining single-cell RNA sequencing data and transcriptomic data to unravel potential mechanisms and signature genes of the progression of idiopathic pulmonary fibrosis to lung adenocarcinoma and predict therapeutic agents

Zhou, X., Tan, F., Zhang, S., & Zhang, T. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01274-y · Cited by 11

GOLM1 Promotes Pulmonary Fibrosis through Upregulation of NEAT1

Wang, Y., Hu, D., Wan, L., Yang, S., Liu, S., Wang, Z., Li, J., Li, J., Zheng, Z., Cheng, C., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0151oc · Cited by 11

Ang-(1–7)/Mas axis ameliorates bleomycin-induced pulmonary fibrosis in mice via restoration of Nox4-Nrf2 redox homeostasis

Sheng, M., Li, Q., Huang, W., Yu, D., Pan, H., Qian, K., Ren, F., Luo, L., & Tang, L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176233 · Cited by 11

Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort

Scheidegger, M., Boubaya, M., Garaiman, A., Barua, I., Becker, M. O., Bjørkekjær, H. J., Bruni, C., Dobrota, R. D., Fretheim, H., Jordan, S., et al. (2024) · RMD Open · doi:10.1136/rmdopen-2023-003658 · Cited by 12

Demethyleneberberine Alleviates Pulmonary Fibrosis through Disruption of USP11 Deubiquitinating GREM1

Ge, C., Huang, M., Han, Y., Shou, C., Li, D., & Zhang, Y. (2024) · Pharmaceuticals · doi:10.3390/ph17030279 · Cited by 11

Elucidating the Molecular Pathways and Therapeutic Interventions of Gaseous Mediators in the Context of Fibrosis

Li, A., Wu, S., Li, Q., Wang, Q., & Chen, Y. (2024) · Antioxidants · doi:10.3390/antiox13050515 · Cited by 11

Micro-CT-assisted identification of the optimal time-window for antifibrotic treatment in a bleomycin mouse model of long-lasting pulmonary fibrosis

Buccardi, M., Grandi, A., Ferrini, E., Buseghin, D., Villetti, G., Civelli, M., Sverzellati, N., Aliverti, A., Pennati, F., & Stellari, F. F. (2024) · Scientific Reports · doi:10.1038/s41598-024-65030-3 · Cited by 11

Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review

Han, M., Liu, Q., Ji, Z., Jin, L., Jin, W., & Gao, Z. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1411279 · Cited by 11

The Fibrotic Phenotype of Human Precision-Cut Lung Slices Is Maintained after Cryopreservation

Marimoutou, M., Patel, V., Kim, J. H., Schaible, N., Alvarez, J., Hughes, J., Obermok, M., Rodríguez, C. I., Kallarakkal, T. G., Suki, B., et al. (2024) · Toxics · doi:10.3390/toxics12090637 · Cited by 11

Lung dECM matrikine-based hydrogel reverses bleomycin-induced pulmonary fibrosis by suppressing M2 macrophage polarization

Zhu, X., Yang, Y., Mao, S., Liu, Q., Li, Y., Yang, Y., Gao, M., Bao, J., Li, W., & Li, Y. (2024) · Biofabrication · doi:10.1088/1758-5090/ada092 · Cited by 11

Genome-wide association study of idiopathic pulmonary fibrosis susceptibility using clinically curated European ancestry datasets

Chin, D., Hernández-Beeftink, T., Donoghue, L. J., Guillén‐Guío, B., Leavy, O. C., Adegunsoye, A., Booth, H., CleanUP-IPF Investigators of the Pulmonary Trials Cooperative, Fahy, W. A., Fingerlin, T. E., et al. (2026) · European Respiratory Journal · doi:10.1183/13993003.00506-2026 · Cited by 11

Ferroptosis: the potential key roles in idiopathic pulmonary fibrosis

Song, L., Fusheng, G., & Man, J. (2025) · European journal of medical research · doi:10.1186/s40001-025-02623-2 · Cited by 11

Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis

Okano, T., Kobayashi, T., Yasuma, T., D’Alessandro‐Gabazza, C. N., Toda, M., Fujimoto, H., Nakahara, H., Okano, Y., Takeshita, A., Nishihama, K., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.593620 · Cited by 11

Effectiveness of Pharmacist–Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone

Satsuma, Y., Ikesue, H., Kusuda, K., Maeda, M., Muroi, N., Mori, R., Kogo, M., Hirabayashi, R., Nagata, K., Nakagawa, A., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.529654 · Cited by 11

Waiting List Dynamics and Lung Transplantation Outcomes After Introduction of the Lung Allocation Score in The Netherlands

Hoffman, T. W., Hemke, A. C., Zanen, P., Luijk, B., Hoek, R. A. S., Verschuuren, E. A. M., & van Kessel, D. A. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001205 · Cited by 11

FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice

Liu, Y., Hou, Q., Wang, R., Liu, Y., & Cheng, Z. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02452-2 · Cited by 11

Fu-Zheng-Tong-Luo formula promotes autophagy and alleviates idiopathic pulmonary fibrosis by controlling the Janus kinase 2/signal transducer and activator of transcription 3 pathway

Zhang, X., Su, J., Lin, J., Liu, L., Wu, J., Yuan, W., Zhang, Y., Chen, Q., Su, Z. J., Xu, G., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116633 · Cited by 11

Evaluation of the possible effect of inspiratory muscle training on inflammation markers and oxidative stress in childhood asthma

Gökçek, Ö. C., Yurdalan, S. U., Tuğay, B. U., El, Ç., & Doğan, S. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-05047-4 · Cited by 11

OGG1 promoted lung fibrosis by activating fibroblasts via interacting with Snail1

Song, C., Xu, Z., Liang, Q., Mu, Y., Liu, M., Wu, Z., Li, X., Li, J., Chen, H., Wang, Y., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111148 · Cited by 11

Safety and tolerability of combination treatment with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis

Lee, J. H., & Song, J. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-946 · Cited by 13

Macrophage expressed tartrate‐resistant acid phosphatase 5 promotes pulmonary fibrosis progression

Bergwik, J., Bhongir, R. K. V., Padra, M., Adler, A., Olm, F., Lång, P., Lindstedt, S., Andersson, G., Egesten, A., & Tanner, L. (2024) · Immunology · doi:10.1111/imm.13748 · Cited by 11

Identification and functional characterization of a novel surfactant protein A2 mutation (p.N207Y) in a Chinese family with idiopathic pulmonary fibrosis

Liu, L., Qin, J., Guo, T., Chen, P., Ouyang, R., Peng, H., & Luo, H. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1393 · Cited by 13

Current strategies and opportunities to manufacture cells for modeling human lungs

Varma, R., Soleas, J. P., Waddell, T. K., Karoubi, G., & McGuigan, A. P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.005 · Cited by 10

Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care

Antoniou, K. M., Tsitoura, E., Vasarmidi, E., Symvoulakis, E. K., Aidinis, V., Tzilas, V., Τzouvelekis, Α., & Bouros, D. E. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.12.007 · Cited by 12

IL-35 subunit EBI3 alleviates bleomycin-induced pulmonary fibrosis via suppressing DNA enrichment of STAT3

Chen, D., Zheng, G., Yang, Q., Luo, L., & Shen, J. (2021) · Respiratory Research · doi:10.1186/s12931-021-01858-x · Cited by 12

When and how important is anti-fibrotic therapy in the post-COVID-19 period?

Kerget, B., Çil, G., Araz, Ö., Alper, F., & Akgün, M. (2022) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2022_105 · Cited by 11

P27 Promotes TGF-β-Mediated Pulmonary Fibrosis via Interacting with MTORC2

Dai, Y.-H., Li, X., Dong, D.-P., Gu, H., Kong, C.-Y., & Xu, Z. (2019) · Canadian Respiratory Journal · doi:10.1155/2019/7157861 · Cited by 11

Triggering AHR resolves TGF-β1 induced fibroblast activation and promotes AT1 cell regeneration in alveolar organoids

Hagan, A. S., Williams, S., Mathison, C. J. N., Yan, S., Nguyen, B., Federe, G. C., Kuzu, G., Siefert, J. C., Hampton, J., Chichkov, V., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08446-5 · Cited by 12

Chicken bone marrow mesenchymal stem cells improve lung and distal organ injury

Niu, H., Song, H., Guan, Y., Zong, X., Niu, R., Zhao, S., Liu, C., Yan, W., Guan, W., & Wang, X. (2021) · Scientific Reports · doi:10.1038/s41598-021-97383-4 · Cited by 10

Therapeutic Effects of Omentin-1 on Pulmonary Fibrosis by Attenuating Fibroblast Activation via AMP-Activated Protein Kinase Pathway

Zhou, Y., Zhang, Y., Cheng, H., Li, X., Feng, D., Yue, S., Xu, J., Xie, H., & Luo, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10112715 · Cited by 10

The Lung Transplant Candidate, Indications, Timing, and Selection Criteria

Mannem, H. C., Aversa, M. M., Keller, T., & Kapnadak, S. G. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.10.001 · Cited by 10

Discovery of a Potent, Selective, and Orally Bioavailable Tool Compound for Probing the Role of Lysophosphatidic Acid Type 2 Receptor Antagonists in Fibrotic Disorders

Armani, E., Rizzi, A., Iotti, N., Saccani, F., Lascia, M. R. D., Tigli, L., Pappani, A., Marchini, G., Murgo, A., Capelli, A. M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02087 · Cited by 10

AT2 cell–derived IgA trapped by the extracellular matrix in silica-induced pulmonary fibrosis

Chen, M., Wang, J., Yuan, M., Min, L., Sun, Y., Wang, S., Luo, W. F., Zhou, Y., Zhang, W., Jiang, W., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110545 · Cited by 10

Harnessing the translational power of bleomycin model: new insights to guide drug discovery for idiopathic pulmonary fibrosis

Murgo, A., Bignami, F., Federico, G., Villetti, G., Civelli, M., Sala, A., & Miglietta, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1303646 · Cited by 11

Neutrophil–lymphocyte ratio in patients with idiopathic pleuroparenchymal fibroelastosis

Suzuki, Y., Kono, M., Hasegawa, H., Hashimoto, D., Yokomura, K., Imokawa, S., Inoue, Y., Hozumi, H., Karayama, M., Furuhashi, K., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-001763 · Cited by 10

Introduction to Lung Disease

Subramaniyan, V., Fuloria, S., Sekar, M., Shanmugavelu, S., Vijeepallam, K., Kumari, U., Narain, K., Meenakshi, D. U., Maziz, M. N. H., & Fuloria, N. K. (2023) · Springer eBooks · doi:10.1007/978-981-99-4780-5_1 · Cited by 10

Identification and validation of potential biomarkers related to oxidative stress in idiopathic pulmonary fibrosis

Du, X. L., Ma, Z., Xing, Y., Feng, L., Li, Y., Dong, C., Ma, X., Huo, R., & Tian, X. (2024) · Immunobiology · doi:10.1016/j.imbio.2024.152791 · Cited by 10

Regulation effect of the intestinal flora and intervention strategies targeting the intestinal flora in alleviation of pulmonary fibrosis development

Guo, J., & Liyang, Y. A. N. G. (2024) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.2023-100 · Cited by 10

Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease

Han, S. J., Kim, H. H., Hyun, D., Ji, W., Choi, C.-M., Kim, H. C., & Kim, H. C. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02946-6 · Cited by 10

Relationship between idiopathic interstitial pneumonias (IIPs) and connective tissue disease-related interstitial lung disease (CTD-ILD): A narrative review

Enomoto, N. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.03.006 · Cited by 12

NBR1-p62-Nrf2 mediates the anti-pulmonary fibrosis effects of protodioscin

Zeng, Q., Wen, B.-B., Liu, X., Luo, Y.-Y., Hu, Z., Huang, L., Zhang, X., Huang, X., Zhou, T., Sang, X., et al. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00930-0 · Cited by 10

Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America

Figueiredo, R. G., Duarte, N. F. V., Campos, D. C. B., Verduzco, M. D. J. D., Márquez, Á. A., de Araújo, G. T. B., & Rubin, A. S. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21050647 · Cited by 10

Progressive pulmonary fibrosis (PPF): Estimation of incidence and treatment rates in Japan using a claims database

Kondoh, Y., Ito, T., Saito, K., Bao, H., & Sakamoto, W. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.05.005 · Cited by 12

Promising advances in treatments for the management of idiopathic pulmonary fibrosis

Sofia, C., Comes, A., Sgalla, G., & Richeldi, L. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2354460 · Cited by 10

Effect of breathing exercises on patients with interstitial lung disease: A systematic review and meta-analysis

Fan, J., Chang, Y., Cheng, S., Liang, B., & Qu, D. (2024) · Quality of Life Research · doi:10.1007/s11136-024-03679-z · Cited by 9

siTGF-β1 and pirfenidone contained Ionizable-Liposomal nanodrug for enhanced treatment of Idiopathic pulmonary fibrosis

Yu, C., Xu, Q., Cao, X., Cheng, S., Zhang, Z., & Huang, J. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.154850 · Cited by 13

Tanshinone IIA Loaded Inhaled Polymer Nanoparticles Alleviate Established Pulmonary Fibrosis

Chen, W., Gao, Y., Liu, Y., Luo, Y., Xue, X., Xiao, C., & Wei, K. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00532 · Cited by 10

The role and therapeutic potential of itaconate in lung disease

He, R., Zuo, Y., Yi, K., Liu, B., Song, C., Li, N., & Geng, Q. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00642-1 · Cited by 11

Tetrandrine Alleviates Pulmonary Fibrosis by Modulating Lung Microbiota‐Derived Metabolism and Ameliorating Alveolar Epithelial Cell Senescence

Zhuo, J., Chu, L., Liu, D., Zhang, J., Chen, W., Huang, H., Yu, Q., Meng, X., Zou, F., Cai, S., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8374 · Cited by 11

Mesenchymal stem cell application in pulmonary disease treatment with emphasis on their interaction with lung-resident immune cells

Hazrati, A., Mirarefin, S. M. J., Malekpour, K., Rahimi, A., Khosrojerdi, A., Rasouli, A., Akrami, S., & Soudi, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1469696 · Cited by 10

The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis

Birker, M., Boucher, M., Ranieri, G., Poirey, S., Studer, R. O., Freti, D., Schnoebelen, M., Froidevaux, S., Morrison, K., Wyss, C., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103396 · Cited by 11

Molecular Imaging of Pulmonary Fibrosis

Allison, M. B., Catana, C., Zhou, I. Y., Caravan, P. D., & Montesi, S. B. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267852 · Cited by 10

Involvement of lncRNA MIR205HG in idiopathic pulmonary fibrosis and IL-33 regulation via Alu elements

Takashima, T., Zeng, C., Murakami, E., Fujiwara, N., Kohara, M., Nagata, H., Feng, Z., Sugai, A., Harada, Y., Ichijo, R., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187172 · Cited by 11

The Role of Bronchoscopy in the Diagnosis of Interstitial Lung Disease: A State-of-the-Art Review

Peralta, A. R., & Shadid, A. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093255 · Cited by 10

Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease

Su, J., Lartey, D. A., Zanella, G., Hawinkels, L. J. A. C., Matteoli, G., Löwenberg, M., & Barnhoorn, M. C. (2025) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf087 · Cited by 14

Pulmonary fibrosis and exosomes: pathways to treatment

Nija, R. J., & Nithya, T. G. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10855-y · Cited by 12

3D in vitro co-culture disc for spatiotemporal image analysis of cancer–stromal cell interaction

Takahashi, H., & Kikuchi, Y. (2021) · Biomaterials Science · doi:10.1039/d1bm00629k · Cited by 10

Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort

Cottin, V., Guéguen, S., Jouneau, S., Nunès, H., Crestani, B., Bonniaud, P., Wémeau-Stervinou, L., Reynaud‐Gaubert, M., Israël‐Biet, D., Cadranel, J. L., et al. (2021) · Respiration · doi:10.1159/000518008 · Cited by 10

Collagen 3D matrices as a model for the study of cell behavior in pulmonary fibrosis

Machahua, C., Vicens‐Zygmunt, V., Ríos-Martín, J., Llatjós, R., Campuzano, I. E., Molina‐Molina, M., & Montes‐Worboys, A. (2022) · Experimental Lung Research · doi:10.1080/01902148.2022.2067265 · Cited by 10

Salt-inducible kinase 2 regulates fibrosis during bleomycin-induced lung injury

van Gijsel‐Bonnello, M., Darling, N. J., Tanaka, T., Carmine, S. D., Marchesi, F., Thomson, S. M., Clark, K., Kurowska‐Stolarska, M., McSorley, H. J., Cohen, P., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102644 · Cited by 11

VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis

Kim, S., Adams, T. S., Hu, Q., Shin, H. J., Chae, G., Lee, S. E., Sharma, L., Kwon, H., Lee, F. Y., Park, H., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0219oc · Cited by 10

Update on diagnosis and treatment of idiopathic pulmonary fibrosis

Martínez, J. A. B., Baldi, B. G., da Costa, C. H., Jezler, S. F. D. O., Lima, M. S., & Rufino, R. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000000152 · Cited by 39

Idiopathic pulmonary fibrosis: an Australian perspective

Prasad, J. D., Holland, A. E., Glaspole, I., & Westall, G. P. (2016) · Internal Medicine Journal · doi:10.1111/imj.13078 · Cited by 10

Management of Idiopathic Pulmonary Fibrosis

Fioret, D., Roman, J., & Perez, R. L. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31821fbdbc · Cited by 10

Lung transplantation for idiopathic pulmonary fibrosis

Pavec, J. L., Dauriat, G., Gazengel, P., Dolidon, S., Hanna, A., Feuillet, S., Pradère, P., Crutu, A., Florea, V., Boulate, D., et al. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104026 · Cited by 29

[Diagnostic criteria and possible treatment of idiopathic pulmonary fibrosis].

Bendstrup, E. M., Hyldgaard, C., & Hilberg, O. (2014) · PubMed · Cited by 2